ANI PHARMACEUTICALS, INC Gain (Loss) Related to Litigation Settlement
ANI PHARMACEUTICALS, INC (ANIP) reported Gain (Loss) Related to Litigation Settlement of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2024-02-29
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for the quarter ending 2022-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for the quarter ending 2022-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for the quarter ending 2021-12-31 was -$350.00K.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for the quarter ending 2021-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for fiscal 2023 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for fiscal 2022 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) related to litigation settlement for fiscal 2021 was -$8.75M.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | -$350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$350.00K derived: sum of 2 quarters · filed 2024-02-29 | -$8.75M derived: sum of 3 quarters · filed 2024-02-29 | -$8.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$8.40M derived: sum of 2 quarters · filed 2022-11-09 | -$8.40M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$8.40M 10-Q · filed 2022-08-08 | -$8.40M 10-Q · filed 2022-08-08 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |